TRANSGEN

The development of vectors for genetic manipulation and gene discovery in mammalian systems

Coordinatore	THE UNIVERSITY OF NOTTINGHAM    more  Organization address address: University Park city: NOTTINGHAM postcode: NG7 2RD contact info Titolo: Mr. Nome: Paul Cognome: Cartledge Email: send email Telefono: +44 115 9515679 Fax: +44 115 9513633
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	200˙549 €
EC contributo	200˙549 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2010-IEF
Funding Scheme	MC-IEF
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-10-01   -   2013-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF NOTTINGHAM  Organization address address: University Park city: NOTTINGHAM postcode: NG7 2RD contact info Titolo: Mr. Nome: Paul Cognome: Cartledge Email: send email Telefono: +44 115 9515679 Fax: +44 115 9513633	UK (NOTTINGHAM)	coordinator	200˙549.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Transposons are important tools in genetics and molecular biology. They are widely used in academic and industrial settings where technical innovations continually expand the range of applications. Transposons are promising tools in synthetic biology and gene therapy applications. The amount of DNA a transposon can carry is in principal unlimited. However, in practice, when transposon length is increased, for example by the addition of a therapeutic transgene, its ability to transpose is reduced. This phenomenon is known as 'length dependence' and limits the efficiency of transposons in gene delivery applications. Although length-dependence is a well documented phenomenon, the causes have not been investigated and remain unclear. We believe that the first step in combating the problem is to understand the underlying causes. We have therefore designed biochemical and genetic assays that will reveal the stage(s) of the transposition reaction at which length-dependence operates. The assays will be used to test those transposons that are currently under the most intensive development as tools in eukaryotic systems. Some of these transposons are reported to be substantially free of length-dependence. Our assays will confirm if this is true, and if so whether this 'immunity' is a property of the respective transposases, of the DNA sequences, or due to the binding of host proteins. One of the attractive features of transposons as gene delivery vectors is that there are a lot to choose from, and different elements will have different advantages and disadvantages with different transgenes in different applications. If we can identify the causes of length-dependence in some elements, and the mechanisms by which it is minimized in others, we may be able to combine the most advantageous features in a single system. The overall aim of the work is to create a highly active transposition system that lacks length dependence.'

Introduzione (Teaser)

Replacing faulty genes is one of the most promising areas in disease therapy. An EU-funded project has explored the potential of jumping genes or transposable elements (TEs) as gene carriers.